CB Expands to Asia, Daiichi Sankyo Looks To Enter Biosimilars Market
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo and U.S. venture CB announced that it will introduce biosimilars of anti-TNFα inhibitor etanercept and anti-CD20 antibody rituximab to Japan, Korea and Taiwan.